 |
0 Diseases |  |
77 Trials |
|
77 Trials |  |
6639 News |  |
| «12345678910111213...8485» |
- | hydrochlorothiazide / Generic mfg., furosemide / Generic mfg.
Journal: The first compound heterozygous mutations in SLC12A3 and PDX1 genes: a unique presentation of Gitelman syndrome with distinct insulin resistance and familial diabetes insights. (Pubmed Central) - Feb 9, 2024
These findings illuminate the potential complex genetic factors influencing glucose metabolism disruptions in GS. This research uncovers a novel combination of SLC12A3 and PDX1 gene mutations in a Gitelman Syndrome patient, revealing intricate genetic factors that potentially disrupt glucose metabolism and shedding light on familial diabetes links.
- | furosemide / Generic mfg.
Retrospective data, Journal, Metastases: Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure. (Pubmed Central) - Feb 7, 2024
In a contemporary, real-world cohort of patients with advanced heart failure, several clinical and echocardiographic characteristics are associated with an increased likelihood of severe tricuspid regurgitation. Patients with severe tricuspid regurgitation have an increased risk of mortality.
- | acetazolamide / Generic mfg., hydrochlorothiazide / Generic mfg., furosemide / Generic mfg.
Journal, Predictive model: An Empirical Predictive Model for Determining the Aqueous Solubility of BCS Class IV Drugs in Amorphous Solid Dispersions. (Pubmed Central) - Feb 6, 2024
The developed empirical model predicted the solubility of the model drugs from the ASDs containing model polymer matrices with an accuracy greater than 80%. The developed empirical model demonstrated robustness and predicted the aqueous solubility of model drugs from the ASDs of model polymer matrices with an accuracy greater than 80%.
- | Journal: Prices, availability and affordability of selected essential medicines for chronic diseases in T (Pubmed Central) - Feb 1, 2024
Glibenclamide, budesonide, gliclazide, and diazepam had low availability and were sold at higher prices than their international reference prices. This research highlights priority areas of action to improve access to affordable medicines for chronic diseases in Ankara, T
- | furosemide / Generic mfg.
Journal: Epidemiological characteristics, etiological spectrum, and outcomes of adult patients with pericardial effusion at a Teaching Hospital in Somalia. (Pubmed Central) - Feb 1, 2024
Two-thirds of the cases (66.6%) were managed with furosemide, 48 (51.6%) patients were treated with an anti-inflammatory, hemodialysis was performed in 24 (25.8%) patients and antituberculous medications were administered to 7 (7.5%) patients...The leading causes of PE were cardiac diseases, uremic pericarditis, TB, and hypothyroidism. PE is a significant cause of morbidity and mortality in Somalia, especially in individuals with renal failure and TB infection.
- | vancomycin / Generic mfg., enalapril / Generic mfg., furosemide / Generic mfg.
Journal: Nephrotoxic drug burden and predictors of exposure among patients with renal impairment in Ethiopia: A multi-center study. (Pubmed Central) - Feb 1, 2024
Furosemide, Enalapril, and vancomycin were the most frequently prescribed nephrotoxic medications. The study suggests that prescribers need to give special attention to older patients who have underlying renal insufficiency, a comorbid condition, and polypharmacy regarding exposure to contraindicated nephrotoxic medication.
- | furosemide / Generic mfg.
Retrospective data, Journal: Furosemide in pediatric intensive care: a retrospective cohort analysis. (Pubmed Central) - Jan 31, 2024
This retrospective study observed similar mortality for patients who received furosemide infusions compared to furosemide injections. More research on furosemide in the ICU could provide insights on fluid management, drug effectiveness, and pharmacologic stewardship for critically ill children.
- | furosemide / Generic mfg., lisinopril / Generic mfg.
Journal: Nephrotic Syndrome in a Child With NPHS2 Mutation. (Pubmed Central) - Jan 31, 2024
Immunosuppresive therapy was stopped, Lizinopril dose was increased and weekly infusions of Albumin/furosemide were initiated to manage edema. This case demonstrates that early genetic testing in children with SRNS avoids prolonged potentially harmful immunosuppressive therapy, allows for timely genetic family counseling, and allows earlier consideration for future living related donor kidney transplantation.
- | furosemide / Generic mfg., ibuprofen / Generic mfg.
Journal: Pharmaceutical and pesticide mixtures in a Mediterranean coastal wetland: comparison of sampling methods, ecological risks, and removal by a constructed wetland. (Pubmed Central) - Jan 26, 2024
The evaluated constructed wetland reduced contaminant loads by 45-73% and reduced the faction of species affected from 25 to 6%. Our study highlights the need of addressing contaminant mixture effects in Mediterranean wetlands and supports the use of constructed wetlands to reduce contaminant loads and risks in areas with high anthropogenic pressure.
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
COR TRIATRIATUM SINISTRUM: A RARE CONGENITAL HEART DISEASE DIAGNOSED IN ADULTHOOD (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_7516;
Cardiac MRI was ordered, confirming the diagnosis.Decision?making: Patient was admitted to the hospital, treated with furosemide, metoprolol succinate, spironolactone, dapagliflozin, and sacubitril-valsartan. This case highlights the diagnosis of cor triatriatum sinister, a rare congenital heart defect, using echocardiography and cardiac MRI.
- THE DUAL DILEMMA: TRANSIENT CONSTRICTIVE PERICARDITIS AND COEXISTENT CHRONIC PLEURAL EFFUSION (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_7511;
TCP is a challenging clinical entity that warrants careful evaluation and management. Further research is needed to understand its underlying mechanisms and optimal treatment strategies.
- ANAPLASMOSIS: FROM MULTI-SYSTEM MAYHEM TO VENTRICULAR TACHYCARDIA IN A HEARTBEAT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_7493;
No cases of HGA resulting in fatal arrhythmia and heart failure are documented. A low suspicion threshold to test for tick-borne illnesses in endemic regions could improve outcomes.
- losartan / Generic mfg., furosemide / Generic mfg.
SAVE MY SISTER FROM SCAD: THE ROLE OF GENETIC TESTING IN SCAD (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_6772;
Genetic variants were previously thought to predispose 5% of SCAD patients, however recent studies suggest a higher frequency at 17%. Many of these variants involve vascular connective tissue disorders.
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
A FATAL CASE OF CABOZANTINIB-INDUCED CARDIOMYOPATHY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_6728;
Although cabozantinib-induced cardiomyopathy remains rare, it can be rapidly fatal if diagnosed late. Our case emphasizes that early surveillance of cardiac function is crucial for patients started on cabozantinib to reduce adverse outcomes.
- TICK-BORNE CARDIOGENIC SHOCK: ELECTRICAL AND MECHANICAL MANIFESTATIONS OF BABESIOSIS (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_6709;
In endemic areas, babesiosis should be considered and investigated appropriately with cases of cardiac involvement reported . This case highlights the necessity of early detection and treatment of babesia in patients presenting with new cardiomyopathy.
- dasatinib / Generic mfg.
DASATINIB-INDUCED HEART FAILURE WITH REDUCED EJECTION FRACTION - A CASE REPORT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_6706;
Although only noticed in several cases, Dasatinib has been reported to cause severe PAH as the primary form of cardiotoxicity. However, only a few cases reported systolic heart failure as a direct result.
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
RAPID SEQUENCE INITIATION OF HEART FAILURE GUIDELINE DIRECTED MEDICAL THERAPY FOR PREOPERATIVE OPTIMIZATION: A COMPREHENSIVE HEART TEAM APPROACH TO COMPLEX CARDIOVASCULAR DISEASE (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_6691;
Sacubitril-valsartan, metoprolol, and furosemide was started at discharge and empagliflozin was started at 1 week. This case demonstrates how patient with complex cardiovascular conditions can be benefit from a heart team approach to improve clinical outcomes.
- losartan / Generic mfg., furosemide / Generic mfg., spironolactone / Generic mfg.
ATYPICAL PRESENTATION OF AL AMYLOID CARDIOMYOPATHY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4925;
Early AL-CM diagnosis is crucial as survival is typically <6 months after heart failure progression. AL-CM can manifest with isolated abdominal distension, emphasizing the need for clinical suspicion, early cardiac imaging, and prompt cardiology referral.
- digoxin / Generic mfg.
CONCURRENT DIGOXIN TOXICITY AND BRASH SYNDROME (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4884;
Digoxin Immune Fab is considered safe and effective treatment, though it is costly and requires monitoring. Prompt recognition of concurrent BRASH syndrome guided initiation of supportive measures to interrupt the cycle of bradycardia and renal hypoperfusion and decrease hyperkalemia-related mortality risk with acute digoxin toxicity.
- Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
LABORATORY AND FUNCTIONAL MONITORING IN A PATIENT WITH CHRONIC MYOCARDITIS POST-COVID-19: CASE REPORT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4875;
Laboratory findings, such as elevated troponin and BNP, have been observed in cases of COVID-19-associated myocarditis and, in this case, correlated with cardiac functional findings, such as EF. The significance of this correlation is uncertain, but it may provide data for the diagnosis and monitoring reverse remodeling of post-COVID-19 DCM in the future.
- furosemide / Generic mfg., milrinone / Generic mfg.
ASD OCCLUDER DEVICE: BAIL OUT STRATEGY FOR IATROGENIC ANTERIOR MITRAL VALVE LEAFLET PERFORATION (Moderated Poster Theater 11) - Jan 26, 2024 - Abstract #ACC2024ACC_4830;
He was admitted for initiation of milrinone and furosemide drips with further evaluation by the heart failure team.Decision?making: The patient was presented with the option of a left ventricular assist device as destination therapy (DT-LVAD) but opted to hold off. We highlight the novel utility of the ASD occluder device as a bail out strategy for anterior MV leaflet perforation as a complication during transcatheter MV repair.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Adempas (riociguat) / Bayer, Merck (MSD)
THE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY ON DIURETIC RESISTANT FLUID RETENTION IN A PATIENT WITH PULMONARY HYPERTENSION AND RIGHT HEART FAILURE (Moderated Poster Theater 10) - Jan 26, 2024 - Abstract #ACC2024ACC_4825;
With uptitration of Remodulin to a dose of 38 ng/kg/min at his 5/1/23 office visit, JS continued to struggle with significant fluid retention despite a furosemide 80 mg twice a day and metolazone 2.5 mg weekly regimen... In obese patients with PAH, GLP-1 RAs can be an effective therapeutic agent to enhance flesh weight loss, resulting in dramatic reversal of diuretic resistant fluid retention in right heart failure.
- furosemide / Generic mfg.
SAFETY AND EFFICACY OF SGLT2 INHIBITORS FOR THE TREATMENT OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (Moderated Poster Theater 02) - Jan 26, 2024 - Abstract #ACC2024ACC_4755;
SGLT2i treatment appeared to improve volume status and combat diuretic resistance, reducing parameters directly correlated with mortality in ATTR-CM. SGLT2 inhibitors may be helpful medications for this disease with limited treatment options.
- Arcalyst (rilonacept) / Regeneron, Kiniksa
A CASE OF TRANSIENT CONSTRICTIVE PERICARDITIS BEING TREATED WITH RILONACEPT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4043;
Optimizing medical therapy is the mainstay of treatment. Pericardiectomy can be challenging and is reserved for refractory cases.
- furosemide / Generic mfg.
FUROSEMIDE-RELATED HYPOTENSION IS RARE IN THE MAJORITY OF PATIENTS TREATED FOR ACUTE HEART FAILURE (Moderated Poster Theater 02) - Jan 26, 2024 - Abstract #ACC2024ACC_3935;
Hypotension due to IVFu is rare in AHF with SBP > 110-120 mmHg and doses of 40-80mg. Most variance in SBP during AHF treatment is due to other factors.
- Henletor (torsemide) / Orchid
MODIFIED ON-TREATMENT ANALYSIS OF THE EFFECTS OF TORSEMIDE VS FUROSEMIDE AFTER DISCHARGE IN PATIENTS HOSPITALIZED WITH HEART FAILURE: RESULTS FROM TRANSFORM-HF (Moderated Poster Theater 02) - Jan 26, 2024 - Abstract #ACC2024ACC_3933;
In TRANSFORM-HF, a more liberal definition of study drug adherence within a modified on-treatment analysis did not meaningfully change original trial results. There remained no significant difference in mortality or hospitalization after HF hospitalization with torsemide vs furosemide.
- furosemide / Generic mfg.
SYSTEM FOR MONITORING AND CONTROLLING VENOUS PRESSURE FOR ABORTING ACUTE PRECIPITATION OVER CHRONIC CONGESTIVE HEART FAILURE (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3828;
There remained no significant difference in mortality or hospitalization after HF hospitalization with torsemide vs furosemide. his experiment is currently being conducted with a larger number of rats, and the final presentation will contain comprehensive data and statistical analysis.
- Henletor (torsemide) / Orchid
SAFETY AND EFFICACY OF TORSEMIDE VERSUS FUROSEMIDE IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3364;
his experiment is currently being conducted with a larger number of rats, and the final presentation will contain comprehensive data and statistical analysis. In comparison with furosemide, patients treated with torsemide had reduced cardiac mortality, improved NYHA class, and decreased drug-induced adverse events.
- furosemide / Generic mfg.
HIGH CARDIAC OUTPUT STATE SECONDARY TO SEVERE POSTPARTUM PREECLAMPSIA: A CASE REPORT HIGHLIGHTING DIAGNOSTIC AND MANAGEMENT STRATEGIES (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3281;
The underlying mechanisms of this phenomenon remain unclear, but it is clinically significant. Managing postpartum preeclampsia primarily involves blood pressure control and preventing end-organ damage.
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
A CASE OF LV NONCOMPACTION AND REDUCED LV SYSTOLIC FUNCTION (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3245;
We report a unique case of LV noncompaction which is seen in 0.24% of patients with heart failure. This case highlights some of the unique findings associated with noncompaction and the uncertainty regarding necessity of anticoagulation for patients with reduced LV systolic function and noncompaction.
- furosemide / Generic mfg., milrinone / Generic mfg.
THE UTILITY OF CARDIAC MRI IN DIAGNOSING LEFT VENTRICULAR NONCOMPACTION SYNDROME (LVNC) (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3235;
cMRI remains the most accurate diagnostic test for LVNC. Referral to a heart failure specialist and cMRI are crucial and can potentially impact treatment and improve outcomes.
- furosemide / Generic mfg.
A RARE CASE OF CONSTRICTIVE PERICARDITIS AND PULMONIC STENOSIS CAUSED BY FIBROSING MEDIASTINITIS (Moderated Poster Theater 11) - Jan 26, 2024 - Abstract #ACC2024ACC_3213;
Referral to a heart failure specialist and cMRI are crucial and can potentially impact treatment and improve outcomes. This case illustrates the importance of recognizing CP and pulmonary artery stenosis as a cause of chest pain and dyspnea in a patient with FM.
- furosemide / Generic mfg.
OUTPATIENT WORSENING OF HEART FAILURE AND MORTALITY IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_2579;
Escalation of outpatient oral loop diuretics is associated with a death rate notably higher than no HF worsening. Outpatient diuretic escalation may serve as a key endpoint in the assessment of future therapies.
- furosemide / Generic mfg.
ESOPHAGEAL FOOD BOLUS-INDUCED LEFT ATRIAL (LA) COMPRESSION: A RARE CULPRIT IN EXACERBATION OF ACUTE HEART FAILURE (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_2510;
Management involved Lasix for acute heart failure exacerbation, Endoscopy (EGD) for disimpaction of esophageal food bolus... Use complementary imaging modalities, such as CT scans, alongside echocardiography to enhance diagnostic accuracy and prevent misdiagnosing LA mass cases.
- furosemide / Generic mfg., warfarin / Generic mfg.
SEVERE RHEUMATIC AORTIC AND MITRAL STENOSIS WITH SEVERE PULMONARY HYPERTENSION IN PREGNANCY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_562;
This case illustrates the complexity of managing multiple VHD in pregnancy. A multidisciplinary approach is recommended to ensure patient and fetal safety.
- | Journal: Identification of Barriers for Active Disease Management and of Medication-Related Problems through Therapeutic Patient Education in Older Home-Care Patients. (Pubmed Central) - Jan 23, 2024
The results of this study revealed some critical aspects related to the treatment path and healthcare professionals. These results will be used to plan educational interventions for polypharmacy patients to improve medication adherence and the understanding and management of diseases.
- |||| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Henletor (torsemide) / Orchid
New P4 trial: DART-HA: Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts (clinicaltrials.gov) - Jan 23, 2024
P4, N=80, Recruiting, Sponsor: Heart Center Research, LLC
- || furosemide / Generic mfg., spironolactone / Generic mfg.
Review, Journal: Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome. (Pubmed Central) - Jan 18, 2024
The trials included no data on health-related quality of life, non-serious adverse events, and liver function associated with the TIPS placement. We identified one ongoing trial and one study awaiting classification which may contribute to the review when information becomes available.
- ||| warfarin / Generic mfg.
Journal, Adverse events: The association between warfarin usage and international normalized ratio increase: systematic analysis of FDA Adverse Event Reporting System (FAERS). (Pubmed Central) - Jan 18, 2024
This effect may be less pronounced in women due to the procoagulatory effects of estrogen signaling. Multiple possible DDIs were identified, including acetaminophen, ramipril, and furosemide.
- | furosemide / Generic mfg.
Trial completion date, Trial primary completion date: FOSTIK: Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation (clinicaltrials.gov) - Jan 17, 2024
P=N/A, N=180, Recruiting, Sponsor: King Chulalongkorn Memorial Hospital
Multiple possible DDIs were identified, including acetaminophen, ramipril, and furosemide. Trial completion date: May 2025 --> May 2027 | Trial primary completion date: May 2024 --> May 2026
- | colistin sulphate / Generic mfg.
Retrospective data, Journal: Risk factors and prognosis for the development of acute kidney injury in patients using colistin in the intensive care unit: A retrospective cohort study. (Pubmed Central) - Jan 16, 2024
Vasoactive agent use, previous kidney injury, and furosemide use were independent risk factors for colistin-induced nephrotoxicity. Considering these factors may be instructive for better monitoring of patients when colistin is required in intensive care units.
- | hydrochlorothiazide / Generic mfg., furosemide / Generic mfg.
Preclinical, Journal: Probing the hair detectability of prohibited substances in sports: an in vivo-in silico-clinical approach and analytical implications compared with plasma, urine, and faeces. (Pubmed Central) - Jan 15, 2024
Anabolic agents were expected in hair, whereas undetectable compounds, such as peptide hormones and beta-2 agonists, were likely due to large molecular mass or high polarity. This study enhances understanding of hair analysis in doping investigations, providing insights into substance detectability.
- | furosemide / Generic mfg.
Biomarker, Journal: Good old-fashioned Lasix: The poor man's early novel kidney biomarker. (Pubmed Central) - Jan 15, 2024
This study enhances understanding of hair analysis in doping investigations, providing insights into substance detectability. No abstract available
- | furosemide / Generic mfg.
Journal, Surgery: Furosemide responsiveness predicts acute kidney injury progression after cardiac surgery. (Pubmed Central) - Jan 15, 2024
FR parameters were inversely associated with risk of AKI progression in patients with mild and moderate AKI after cardiac surgery. The addition of FR parameters significantly improved prediction for AKI progression based on baseline clinical models.
- | dorzolamide / Generic mfg., furosemide / Generic mfg.
Journal, Immune cell: Methazolamide Reduces the AQP5 mRNA Expression and Immune Cell Migration-A New Potential Drug in Sepsis Therapy? (Pubmed Central) - Jan 15, 2024
Incubation with methazolamide (10 M) and furosemide (10 M) reduced AQP5 mRNA and protein expression by about 30% in REH cells...However, after LPS administration, the reduction in AQP5 expression by methazolamide is no longer possible. Hence, our study indicates that methazolamide is capable of reducing AQP5 expression and has the potential to be used in sepsis prophylaxis.
- || furosemide / Generic mfg.
Review, Journal: Diuretics use in the management of bronchopulmonary dysplasia in preterm infants: A systematic review. (Pubmed Central) - Jan 12, 2024
Conducting large prospective studies of good quality could provide more definitive insights, but the rarity of outcomes and eligible patients poses challenges. Further research, primarily focusing on RCTs assessing diuretics' safety and efficacy in this population, is warranted.
- || Henletor (torsemide) / Orchid
Review, Journal: Diuretic Strategies in Acute Decompensated Heart Failure: A Narrative Review. (Pubmed Central) - Jan 11, 2024
PubMed, OVID, and Embase databases were searched from inception to December 22, 2022, with the following search terms: heart failure, acute heart failure, decompensated heart failure, furosemide, bumetanide, ethacrynic acid, hydrochlorothiazide, indapamide, metolazone, chlorthalidone, spironolactone, eplerenone, and acetazolamide...Trials involving torsemide, chlorothiazide, and tolvaptan were excluded...Heart failure with congestion can be managed with careful administration of high-dose loop diuretics, supported by thiazides and acetazolamide when necessary. Clinical trials are underway to further evaluate this strategy.
- Comparative analysis of a targeted pharmacogenomics array panel and genome sequencing in a neonate on extracorporeal membrane oxygenation (MTCC - Exhibit Halls DE) - Jan 10, 2024 - Abstract #ACMG2024ACMG_812;
These findings suggest that both GS and a PGx array are needed for a comprehensive analysis of PGx variants. We aim to complete the PGx analysis of the remaining 24 ECMO cases that are part of this pilot study.
- furosemide / Generic mfg.
Efficacy and Safety of SGLT2 Inhibitors in Patients with a LVAD (Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1929;
MAP was significantly decreased from baseline to 1 year (p<0.05) (Figure 3).Conclusion In a large cohort of LVAD patients, SGLT2 inhibitors were well tolerated, reduced blood pressure and diuretic burden, improved GDMT utilization, and did not increase heart failure hospitalizations compared to national averages. Further prospective evaluation will confirm these results and determine if SGLT2 inhibitors improve clinical outcomes in LVAD patients.
- | vancomycin / Generic mfg., furosemide / Generic mfg.
Observational data, Journal: Prevalence, risk factors, and outcomes of acute kidney injury in a pediatric cardiac intensive care unit: A cross-sectional study. (Pubmed Central) - Jan 8, 2024
Further prospective evaluation will confirm these results and determine if SGLT2 inhibitors improve clinical outcomes in LVAD patients. In the multivariable analysis, vancomycin intake (odds ratio [OR]: 2.109, 95% confidence interval [CI]: 1.15-3.84), angiography (OR: 4.38, 95% CI: 1.28-14.93), and mechanical ventilation (OR: 2.08, 95% CI: 1.02-4.23) were independent risk factors of AKI development and patients with AKI had a higher in-hospital mortality rate (OR: 5.81, 95% CI: 2.55-13.19), higher need for cardiopulmonary resuscitation